• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

影响 5 个或以上脑转移瘤患者立体定向放射外科治疗效果的因素。

Factors influencing the outcome of stereotactic radiosurgery in patients with five or more brain metastases.

机构信息

Centre hospitalier universitaire de Sherbrooke, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, QC.

出版信息

Curr Oncol. 2019 Feb;26(1):e64-e69. doi: 10.3747/co.25.4244. Epub 2019 Feb 1.

DOI:10.3747/co.25.4244
PMID:30853811
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6380647/
Abstract

BACKGROUND

Stereotactic radiosurgery (srs) for patients with 5 or more brain metastases (bmets) is a matter of debate. We report our results with that approach and the factors influencing outcome.

METHODS

In the 103 patients who underwent srs for the treatment of 5 or more bmets, primary histology was non-small-cell lung cancer (57% of patients). All patients were grouped by Karnofsky performance status and recursive partitioning analysis (rpa) classification. In our cohort, 72% of patients had uncontrolled extracranial disease, and 28% had stable or responding systemic disease. Previous irradiation for 1-4 bmets had been given to 56 patients (54%). The mean number of treated bmets was 7 (range: 5-19), and the median cumulative bmets volume was 2 cm (range: 0.06-28 cm).

RESULTS

Multivariate analyses showed that stable extracranial disease ( < 0.001) and rpa ( = 0.022) were independent prognostic factors for overall survival (os). Moreover, a cumulative treated bmets volume of less than 6 cm (adjusted hazard ratio: 2.54; = 0.006; 95% confidence interval: 1.30 to 4.99) was associated with better os. The total number of bmets had no effect on survival ( = 0.206). No variable was found to be predictive of local control. The rpa was significant ( = 0.027) in terms of distant recurrence.

CONCLUSIONS

Our study suggests that srs is a reasonable option for the management of patients with 5 or more bmets, especially with a cumulative treatment volume of less than 6 cm.

摘要

背景

对于 5 个或以上脑转移瘤(BMETs)的患者,立体定向放射外科(SRS)的应用存在争议。我们报告了采用该方法治疗 5 个或以上 BMETs 的结果以及影响疗效的因素。

方法

103 例接受 SRS 治疗 5 个或以上 BMETs 的患者中,原发性组织学为非小细胞肺癌(57%的患者)。所有患者按 Karnofsky 表现状态和递归分区分析(RPA)分类分组。在我们的队列中,72%的患者有不可控制的颅外疾病,28%的患者有稳定或应答的全身疾病。56 例(54%)患者之前接受过 1-4 个 BMETs 的放疗。治疗的 BMETs 数量中位数为 7(范围:5-19),累积 BMETs 体积中位数为 2cm(范围:0.06-28cm)。

结果

多变量分析表明,稳定的颅外疾病(<0.001)和 RPA(=0.022)是总生存(OS)的独立预后因素。此外,累积治疗 BMETs 体积小于 6cm(调整后的危险比:2.54;=0.006;95%置信区间:1.30 至 4.99)与更好的 OS 相关。BMETs 的总数对生存没有影响(=0.206)。没有变量可以预测局部控制。RPA 对远处复发具有显著意义(=0.027)。

结论

我们的研究表明,SRS 是治疗 5 个或以上 BMETs 的合理选择,尤其是累积治疗体积小于 6cm 的患者。

相似文献

1
Factors influencing the outcome of stereotactic radiosurgery in patients with five or more brain metastases.影响 5 个或以上脑转移瘤患者立体定向放射外科治疗效果的因素。
Curr Oncol. 2019 Feb;26(1):e64-e69. doi: 10.3747/co.25.4244. Epub 2019 Feb 1.
2
Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.2 期立体定向放射外科治疗 ≥ 2 cm 的脑转移瘤的影响。
J Neurosurg. 2018 Aug;129(2):366-382. doi: 10.3171/2017.3.JNS162532. Epub 2017 Sep 22.
3
Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.基于直线加速器的立体定向放射外科治疗5个或更多放射性抵抗性黑色素瘤脑转移瘤的潜在作用。
J Neurosurg. 2015 Nov;123(5):1261-7. doi: 10.3171/2014.12.JNS141919. Epub 2015 Jul 3.
4
Application of recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotactic radiosurgery for newly diagnosed brain metastases.递归划分分析的应用以及对接受立体定向放射外科治疗的新诊断脑转移患者全脑放疗使用情况的评估。
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):993-9. doi: 10.1016/s0360-3016(00)00527-7.
5
Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.伽玛刀治疗肺癌脑转移瘤后生活质量和生存的预测因素:一项前瞻性研究。
J Neurosurg. 2018 Jul;129(1):71-83. doi: 10.3171/2017.2.JNS161659. Epub 2017 Aug 18.
6
Follow-up results of brain metastasis patients undergoing repeat Gamma Knife radiosurgery.行重复伽玛刀放射外科治疗的脑转移瘤患者的随访结果。
J Neurosurg. 2016 Dec;125(Suppl 1):2-10. doi: 10.3171/2016.6.GKS161404.
7
Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2-9 versus 10 or more tumors.立体定向放射外科治疗多发脑转移瘤患者:一项病例匹配研究,比较2 - 9个肿瘤患者与10个或更多肿瘤患者的治疗结果。
J Neurosurg. 2014 Dec;121 Suppl:16-25. doi: 10.3171/2014.8.GKS141421.
8
Gamma Knife radiosurgery for brain metastases from pulmonary large cell neuroendocrine carcinoma: a Japanese multi-institutional cooperative study (JLGK1401).伽玛刀放射外科治疗肺大细胞神经内分泌癌脑转移:一项日本多机构合作研究(JLGK1401)。
J Neurosurg. 2016 Dec;125(Suppl 1):11-17. doi: 10.3171/2016.7.GKS161459.
9
Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients.立体定向放射外科单独治疗与手术切除加全脑放疗治疗递归分区分析1级和2级患者的1或2个脑转移瘤的疗效比较
Cancer. 2007 Jun 15;109(12):2515-21. doi: 10.1002/cncr.22729.
10
Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis.颅内转移瘤切除床的立体定向放射外科治疗与软脑膜癌病风险
J Neurosurg. 2014 Dec;121 Suppl:75-83. doi: 10.3171/2014.6.GKS14708.

引用本文的文献

1
Discovery of increased number or interval growth of brain metastases on same-day GammaKnife™ planning MRI: Predicting factors and patient outcomes.在同一天的伽玛刀™计划MRI上发现脑转移瘤数量增加或间隔生长:预测因素及患者预后
J Radiosurg SBRT. 2022;8(3):189-199.
2
Analysis of Key Clinical Variables and Radiological Manifestations Associated with the Treatment Response of Patients with Brain Metastases to Stereotactic Radiosurgery.脑转移瘤患者立体定向放射治疗反应相关关键临床变量及影像学表现分析
J Clin Med. 2022 Aug 3;11(15):4529. doi: 10.3390/jcm11154529.
3
Treatment of brain metastases from gastrointestinal primaries: Comparing whole-brain radiotherapy and stereotactic radiosurgery in terms of survival.胃肠道原发性肿瘤脑转移的治疗:全脑放疗与立体定向放射外科手术在生存率方面的比较。
North Clin Istanb. 2021 Feb 11;9(1):47-56. doi: 10.14744/nci.2021.65725. eCollection 2022.
4
Local failure after stereotactic radiosurgery (SRS) for intracranial metastasis: analysis from a cooperative, prospective national registry.立体定向放射外科治疗颅内转移瘤后局部失败:一项合作性、前瞻性全国登记研究的分析。
J Neurooncol. 2021 Apr;152(2):299-311. doi: 10.1007/s11060-021-03698-7. Epub 2021 Jan 22.
5
Executive summary from American Radium Society's appropriate use criteria on neurocognition after stereotactic radiosurgery for multiple brain metastases.美国镭射医学会关于立体定向放射外科治疗多发性脑转移瘤后神经认知功能适当应用标准的执行摘要。
Neuro Oncol. 2020 Dec 18;22(12):1728-1741. doi: 10.1093/neuonc/noaa192.

本文引用的文献

1
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).纳武利尤单抗对比多西他赛用于既往接受过治疗的晚期非小细胞肺癌患者:两项随机、开放标签、III期试验(CheckMate 017和CheckMate 057)的两年结果
J Clin Oncol. 2017 Dec 10;35(35):3924-3933. doi: 10.1200/JCO.2017.74.3062. Epub 2017 Oct 12.
2
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.维莫非尼治疗 BRAFV600 突变阳性转移性黑色素瘤患者:BRIM-3 研究的最终总生存结果。
Ann Oncol. 2017 Oct 1;28(10):2581-2587. doi: 10.1093/annonc/mdx339.
3
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.Durvalumab 用于 III 期非小细胞肺癌放化疗后的治疗。
N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.
4
Dabrafenib plus trametinib in patients with BRAF-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.达拉非尼联合曲美替尼治疗BRAF突变型黑色素瘤脑转移患者(COMBI-MB):一项多中心、多队列、开放标签的2期试验。
Lancet Oncol. 2017 Jul;18(7):863-873. doi: 10.1016/S1470-2045(17)30429-1. Epub 2017 Jun 4.
5
Cumulative volumetric analysis as a key criterion for the treatment of brain metastases.累积体积分析作为脑转移瘤治疗的关键标准。
J Clin Neurosci. 2017 May;39:142-146. doi: 10.1016/j.jocn.2016.12.006. Epub 2017 Jan 11.
6
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.瑞博西尼作为激素受体阳性晚期乳腺癌的一线治疗方案
N Engl J Med. 2016 Nov 3;375(18):1738-1748. doi: 10.1056/NEJMoa1609709. Epub 2016 Oct 7.
7
Response assessment criteria for brain metastases: proposal from the RANO group.脑转移瘤反应评估标准: RANO 小组的建议。
Lancet Oncol. 2015 Jun;16(6):e270-8. doi: 10.1016/S1470-2045(15)70057-4. Epub 2015 May 27.
8
Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline.新诊断脑转移瘤的放射治疗与手术管理:美国放射肿瘤学会循证指南
Pract Radiat Oncol. 2012 Jul-Sep;2(3):210-225. doi: 10.1016/j.prro.2011.12.004. Epub 2012 Jan 30.
9
Gamma knife radiosurgery for the management of cerebral metastases from non-small cell lung cancer.伽玛刀放射外科治疗非小细胞肺癌脑转移瘤
J Neurosurg. 2015 Apr;122(4):766-72. doi: 10.3171/2014.12.JNS141111. Epub 2015 Feb 6.
10
Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines.中枢神经系统癌症,2014年第2.2版。NCCN指南的重点更新内容。
J Natl Compr Canc Netw. 2014 Nov;12(11):1517-23. doi: 10.6004/jnccn.2014.0151.